related documents
- Does early palliative care reduce end-of-life hospital costs? A propensity-score matched, population-based, cohort study. Conferences
- EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma. Conferences
- Feasibility of a child life specialist program for oncology patients with minor children at home: Demand and implementation. Conferences
- Feasibility of a child life specialist program for oncology patients with minor children at home: Qualitative analysis. Conferences
- Fostering interspeciality learning in cancer survivorship care: Learning suite results. Conferences
- Health-related quality of life in the treatment and survivorship phases of breast cancer. Conferences
- ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of continuous cycles of carboplatin-based chemotherapy with focus on nausea: A MASCC emesis study group, prospective, observational, real-world multi-centric study. Conferences
- Myocardial injury after gynecologic oncology surgery in septuagenarians and octogenarians: Is there a role for routine postoperative cardiac biomarker monitoring? Conferences
- PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center. Conferences
- Recurrent disease in patients with stage III melanoma in the era of adjuvant immune and targeted therapy. Conferences
- Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and curative esophagectomy: A systematic review and meta-analysis. Conferences
- Should we routinely screen for frailty prior to gynecologic oncology surgery? Frailty as a potential predictor of adverse postoperative outcomes in elderly patients. Conferences
- Technology interventions to support adherence to oral oncolytic agents: A systematic review and meta-analysis. Conferences
- The PROVIEW+ tool: Developing and validating a tool to predict risk of poor performance status and severe symptoms in cancer patients over time. Conferences